Literature DB >> 10674483

Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice.

M Grandbois1, M Morissette, S Callier, T Di Paolo.   

Abstract

The activity of steroids was studied in 1-methyl-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned retired breeder C57BL/6 male mice as a model of Parkinson's disease. Steroids were injected daily for 5 days before MPTP (4 injections, 15 mg/kg i.p., at 2 h intervals) and hormonal treatment continued for 5 more days. Mice that received 17beta-estradiol or progesterone or raloxifene (a selective estrogen receptor modulator) and MPTP had striatal concentrations of dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) similar to those in control animals, whereas mice that received MPTP alone or with 17alpha-estradiol (the isomer with weak estrogenic activity) had an extensive decrease of DA and its metabolites. These results suggest stereospecific prevention of MPTP-induced dopamine loss by 17beta-estradiol, which is also observed with progesterone and raloxifene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674483     DOI: 10.1097/00001756-200002070-00024

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  23 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

Review 2.  Functional aspects of estrogen neuroprotection.

Authors:  Veronica Bisagno; Rachel Bowman; Victoria Luine
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 3.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 4.  Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?

Authors:  Rachel Saunders-Pullman
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

5.  The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.

Authors:  Gurdeep Marwarha; Turk Rhen; Trevor Schommer; Othman Ghribi
Journal:  J Neurochem       Date:  2011-10-24       Impact factor: 5.372

6.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

7.  Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease.

Authors:  Roberto Cosimo Melcangi; Donatella Caruso; Giovanna Levandis; Federico Abbiati; Marie-Therese Armentero; Fabio Blandini
Journal:  J Mol Neurosci       Date:  2011-06-14       Impact factor: 3.444

8.  Risk of Parkinson's disease after tamoxifen treatment.

Authors:  Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash
Journal:  BMC Neurol       Date:  2010-04-12       Impact factor: 2.474

9.  Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system.

Authors:  D E Dluzen; J L McDermott; L I Anderson
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

Review 10.  Estrogen and Alzheimer's disease: the story so far.

Authors:  Brenna Cholerton; Carey E Gleason; Laura D Baker; Sanjay Asthana
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.